When will generic Wegovy be available?

Since receiving approval from the US Food and Drug Administration (FDA) in 2021, Wegovy (semaglutide) has driven impressive weight loss results for many people. In fact, research shows that individuals lose roughly 11% of their body weight within six months of starting treatment. 

Given the drug’s high list price, though, it’s natural to wonder when generic Wegovy will be available. Ahead, we take a closer look. 

No, currently, there is no generic version of Wegovy — or any GLP-1 drug with semaglutide as its active ingredient, for that matter. That means there also isn’t a generic for Ozempic or Rybelsus. The only GLP-1 drugs with generic versions beginning to emerge include:

• Liraglutide (generic for Victoza and Saxenda)

• Exenatide (generic for Byetta and Bydureon)

If you see a generic version of Wegovy being advertised online, don’t trust it. It could be a counterfeit medication that’s unsafe to take, and it may not even contain the same active ingredient as Wegovy.

See if you qualify

The earliest a generic Wegovy could be available is 2041. That’s the year that the last patent on semaglutide expires. 

Novo Nordisk, the manufacturer of Wegovy, currently holds the patents for semaglutide, which includes specific brand-name drugs like Wegovy, Ozempic, and Rybelsus. Until its patents expire, other companies generally cannot market their own semaglutide medications in the US.

Novo Nordisk’s patents include protections for not only the active ingredient (semaglutide) but also the delivery mechanism for the medication, such as Wegovy and Ozempic’s prefilled injection pens.

Given that it’s 2026, you may be (very reasonably) wondering why a generic Wegovy is so far away. Let us explain. 

Before a brand-name drug ever hits the market, it has to undergo extensive clinical trials to prove its safety and efficacy for FDA approval. To help the drugmaker recoup its costs (and encourage future pharmaceutical research), patents provide a period of market exclusivity. In the US, drug patents usually last about 20 years from the date the patent is filed. 

During that time, other companies generally cannot market a generic or brand-name drug with the same active ingredient. And even after a patent expires, it can still take time for a generic to become available. That’s because generic manufacturers need to develop their version of the drug, submit it to the FDA for approval, and then scale up manufacturing.

It’s possible that a generic Ozempic could become available first because its patent expires earlier. However, this still wouldn’t technically be a generic Wegovy since Ozempic comes in lower dosage strengths. And while it can be prescribed off-label for weight loss, Ozempic typically produces less weight loss than Wegovy.

It’s tough to predict the future, but in general, generic medications tend to be 20%–80% cheaper than the brand-name drugs. The biggest factor in where a generic drug price falls within that range is the amount of competition. In other words, the more manufacturers that make generic Wegovy, the cheaper it will be.

However, generic Wegovy may still fall on the more expensive side, at least for injectable options. Wegovy’s injection pen device may be more complicated to manufacture than a tablet of oral semaglutide. 

The good news is that the price of Wegovy is already going down. Up until 2026, the price of Wegovy without insurance was over $1,000. 

Now, you can get the drug for a cash price of $149–$349 per month on Ro (once it’s prescribed). The Wegovy pill costs less than the injection, and prices vary by dosage:

*These prices are available for a limited time only to new patients. Starting April 16, 2026, the 4 mg dose of the Wegovy pill will cost $199 per month. Starting April 1, 2026, the 0.25 mg and 0.5 mg doses of the Wegovy injection will cost $349 per month.

For people with insurance, the cost of Wegovy can be as low as $25 per month with the Wegovy Savings Offer from Novo Nordisk. To be eligible, you must have commercial insurance that includes coverage for Wegovy. People with Medicare, Medicaid, or other government-funded insurance plans cannot use this offer.

Speaking of Medicare, the government negotiated lower prices for Wegovy, Ozempic, and Rybelsus. These prices go into effect in 2027 and are expected to lower the cost of Wegovy by 71%. 

Also, the annual out-of-pocket costs for Medicare Part D are capped at $2,100 starting in 2026. (Even though this doesn’t change the price of Wegovy for this year, it does limit how much you’ll have to pay for it.)

Finally, insurance co-pays for Wegovy may go down in the coming years. Novo Nordisk recently announced that the drug’s list price will be lowered from over $1,000 to $675, which may make insurers more likely to cover it.

While you wait for a generic Wegovy to become available, there are some other generic GLP-1s starting to enter the market.

Generic liraglutide

Generic liraglutide is available for Victoza, which is a lower-strength version FDA-approved for type 2 diabetes. The generic is not currently available in doses that would be equivalent to Saxenda, which is a higher-strength version approved for weight loss. 

While the generic for Victoza can be prescribed off-label for weight loss, its lower dose means it is less effective than brand name Saxenda for weight loss. 

In clinical trials, Saxenda produced an average weight loss of 8% in about one year. By comparison, people taking Wegovy lost about 15% in 68 weeks (about a year and four months).

Generic exenatide

Generic exenatide is another potential generic GLP-1 medication that may eventually become available. However, it is not currently FDA-approved in the US.

In a study conducted in China, generic exenatide performed similarly to the brand-name medication Byetta, which is approved for type 2 diabetes and is sometimes prescribed off-label for weight loss. However, generic versions have not yet been approved by the FDA, so they are not available for prescription in the US at this time.

In a small study of people with obesity, just over half of participants taking exenatide (using dosing similar to Byetta) lost 5% or more of their body weight in approximately three months. By comparison, people taking Wegovy lost around 6% of their body weight by three months and nearly 11% by six months on average in clinical trials.

Compounded semaglutide

Another option is compounded semaglutide, though it’s neither a true generic nor an FDA-approved option. The FDA allows pharmacies to compound drugs when the FDA-approved version is in shortage, something that has previously affected Wegovy. Compounded medications may also be prepared for patients who need a formulation different from the commercially available product.

It’s important to note that compounded medications do not go through the same FDA approval process or review for safety, quality, or effectiveness. They may also differ slightly from the brand-name drug in their ingredients or formulation, which could affect their efficacy or safety. 

However, compounded versions are often less expensive than brand-name medications.

Check for free

There is no generic Wegovy available today, and there likely won’t be for some time. Here’s what you need to know:

• The earliest generic Wegovy may be available is 2041, when the last of Novo Nordisk’s patents on semaglutide expires.

• Generic Ozempic may be available before then and could be prescribed off-label for weight loss.

• When generic Wegovy is available, generic Wegovy could cost up to 80% less than the brand-name drug, but the price depends heavily on competition.

• For now, the most affordable way to get Wegovy is through your insurance (if it’s covered), a cash-pay option through telehealth services like Ro, or through a manufacturer savings program.

• Other generic GLP-1s include liraglutide. Exenatide is also emerging as a generic GLP-1, but it isn’t available in the US yet.